Bavarian Nordic GmbH is a 100-percent subsidiary of the Danish Bavarian Nordic A/S and conducts research, development, manufacturing and marketing of vaccines at its Martinsried site. The site develops and optimizes prophylactic and therapeutic vaccines; the MVA platform serves as the basis for the approved MPox vaccine and a clinical-stage equine encephalomyelitis candidate. In 2024 the company generated only intra-group revenues amounting to TEUR 47,574, which are invoiced monthly to the parent company under a cost-plus contract. On average in 2024 304 full-time equivalents (FTE) were employed and revenues were composed of TEUR 12,728 Commercial and TEUR 34,846 R&D income.
Forschung und Entwicklung auf dem Gebiet der pharmazeutischen Industrie sowie Herstellung von und Handel mit pharmazeutischen Produkten unter Einschluss von Produkten für therapeutische und gentherapeutische Anwendungen.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) München Local Court, HRB 155872 (as of 29 August 2026)
Source: German Commercial Register (Handelsregister) München Local Court, HRB 155872 (as of 29 August 2026)
Source: German Commercial Register (Handelsregister) München Local Court, HRB 155872 (as of 29 August 2026)
Sign in to download data
Source: German Commercial Register (Handelsregister) München Local Court, HRB 155872 (as of 29 August 2026)
Sign in to view detailed salary and cost trends.
